Vascular Calcification in Chronic Kidney Disease

  • M. I. Yilmaz
  • K. Matsubara
  • P. Stenvinkel
  • B. Lindholm
  • Rajnish Mehrotra

Vascular calcification (VC) of medium-sized muscular and large elastic arteries and arterioles is an important complication of uremia, which is closely linked to, and can therefore serve as a marker of, atherosclerosis as well as of arteriosclerosis. There are two forms of VC depending on whether it occurs in the intima or media of blood vessels. Intimal calcification occurs in atherosclerotic lesions [1, 2], and as atherosclerotic plaques mature they typically develop associated calcification [3].


Chronic Kidney Disease Peritoneal Dialysis Coronary Artery Calcification Vascular Calcification Coronary Artery Calcification Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15 (12): 2959–2964.PubMedGoogle Scholar
  2. 2.
    Hunt JL, Fairman R, Mitchell ME, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33 (5): 1214–1219.PubMedGoogle Scholar
  3. 3.
    Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66 (4): 1315–1333.PubMedGoogle Scholar
  4. 4.
    Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24 (7): 1161–1170.PubMedGoogle Scholar
  5. 5.
    Monckeberg J. Uber die reine mediverkalkung der extremitaten-arteries und ihr Verhalten zur arteriosklerose. Virchows Arch 1903; 171: 141–167.Google Scholar
  6. 6.
    Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15 (2): 218–223.PubMedGoogle Scholar
  7. 7.
    Schinke T, Karsenty G. Vascular calcification – a passive process in need of inhibitors. Nephrol Dial Transplant 2000; 15 (9): 1272–1274.PubMedGoogle Scholar
  8. 8.
    Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996; 94 (5): 1175–1192.PubMedGoogle Scholar
  9. 9.
    O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 2000; 102 (1): 126–140.PubMedGoogle Scholar
  10. 10.
    Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005; 111 (10): 1313–1320.PubMedGoogle Scholar
  11. 11.
    Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342 (20): 1478–1483.PubMedGoogle Scholar
  12. 12.
    Hujairi NM, Afzali B, Goldsmith DJ. Cardiac calcification in renal patients: what we do and don't know. Am J Kidney Dis 2004; 43 (2): 234–243.PubMedGoogle Scholar
  13. 13.
    Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95 (6): 560–567.PubMedGoogle Scholar
  14. 14.
    Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106 (1): 100–105.PubMedGoogle Scholar
  15. 15.
    Mehrotra R. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J Ren Nutr 2006; 16 (2): 100–118.PubMedGoogle Scholar
  16. 16.
    Moe SM, O'Neill KD, Fineberg N, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18 (6): 1152–1158.PubMedGoogle Scholar
  17. 17.
    Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004; 65 (5): 1790–1794.PubMedGoogle Scholar
  18. 18.
    Nitta K, Akiba T, Suzuki K, et al. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004; 27 (8): 527–533.PubMedGoogle Scholar
  19. 19.
    London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18 (9): 1731–1740.PubMedGoogle Scholar
  20. 20.
    Mehrotra R. The continuum of chronic kidney disease and end-stage renal disease: challenges and opportunities for chronic peritoneal dialysis in the United States. Perit Dial Int 2007; 27 (2): 125–130.PubMedGoogle Scholar
  21. 21.
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (2 suppl. 3): S112–S119.PubMedGoogle Scholar
  22. 22.
    Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15 (5): 329–337.PubMedGoogle Scholar
  23. 23.
    Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension 2005; 45 (6): 1042–1049.PubMedGoogle Scholar
  24. 24.
    Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12 (12): 2747–2752.PubMedGoogle Scholar
  25. 25.
    Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38 (4): 938–942.PubMedGoogle Scholar
  26. 26.
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15 (7): 1943–1951.PubMedGoogle Scholar
  27. 27.
    Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004; 8 (1): 54–58.PubMedGoogle Scholar
  28. 28.
    London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16 (2): 85–94.PubMedGoogle Scholar
  29. 29.
    Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63 (5): 1852–1860.PubMedGoogle Scholar
  30. 30.
    London GM, Marchais SJ, Safar ME, et al. Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990; 37 (1): 137–142.PubMedGoogle Scholar
  31. 31.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15 (8): 2208–2218.PubMedGoogle Scholar
  32. 32.
    Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 2000; 54 (4): 318–324.PubMedGoogle Scholar
  33. 33.
    Shigematsu T, Kono T, Satoh K, et al. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18 (suppl. 3): iii86–iii89.PubMedGoogle Scholar
  34. 34.
    Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15 (7): 1014–1021.PubMedGoogle Scholar
  35. 35.
    Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16 (6): 1788–1793.PubMedGoogle Scholar
  36. 36.
    Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33 (3): 523–534.PubMedGoogle Scholar
  37. 37.
    Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R, 3rd. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66 (5): 790–796.PubMedGoogle Scholar
  38. 38.
    Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS. Soft tissue calcification in chronic dialysis patients. Am J Pathol 1977; 86 (2): 403–424.PubMedGoogle Scholar
  39. 39.
    Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38 (5): 931–936.PubMedGoogle Scholar
  40. 40.
    Meema HE, Oreopoulos DG. Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Radiology 1986; 158 (3): 671–677.PubMedGoogle Scholar
  41. 41.
    Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32 (3): 388–394.PubMedGoogle Scholar
  42. 42.
    Raggi P, Callister TQ, Cooil B. Calcium scoring of the coronary artery by electron beam CT: how to apply an individual attenuation threshold. AJR Am J Roentgenol 2002; 178 (2): 497–502.PubMedGoogle Scholar
  43. 43.
    Budoff MJ, Yu D, Nasir K, et al. Diabetes and progression of coronary calcium under the influence of statin therapy. Am Heart J 2005; 149 (4): 695–700.PubMedGoogle Scholar
  44. 44.
    Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ. Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management. Am Heart J 2001; 141 (4): 637–644.PubMedGoogle Scholar
  45. 45.
    Lembcke A, Hein PA, Dohmen PM, et al. Pictorial review: electron beam computed tomography and multislice spiral computed tomography for cardiac imaging. Eur J Radiol 2006; 57 (3): 356–367.PubMedGoogle Scholar
  46. 46.
    Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43 (3): 572–579.PubMedGoogle Scholar
  47. 47.
    Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006; 70 (9): 1623–1628.PubMedGoogle Scholar
  48. 48.
    Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16 (2): 520–528.PubMedGoogle Scholar
  49. 49.
    Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67 (3): 1179–1187.PubMedGoogle Scholar
  50. 50.
    Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87 (2): E10–E17.PubMedGoogle Scholar
  51. 51.
    Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63 (3): 1003–1011.PubMedGoogle Scholar
  52. 52.
    Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15 (11): 2857–2867.PubMedGoogle Scholar
  53. 53.
    Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39 (4): 695–701.PubMedGoogle Scholar
  54. 54.
    Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15 (5): 458–482.PubMedGoogle Scholar
  55. 55.
    Garcia GM, McCord GC, Kumar R. Hydroxyapatite crystal deposition disease. Semin Musculoskelet Radiol 2003; 7 (3): 187–193.PubMedGoogle Scholar
  56. 56.
    Vestergaard P, Mosekilde L. Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World J Surg 2003; 27 (3): 343–349.PubMedGoogle Scholar
  57. 57.
    Slatopolsky E, Martin K, Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol 1980; 239 (2): F1–F12.PubMedGoogle Scholar
  58. 58.
    Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9 (4): 355–362.PubMedGoogle Scholar
  59. 59.
    Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992; 41 (1): 161–165.PubMedGoogle Scholar
  60. 60.
    Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 1994; 41 (5): 290–296.PubMedGoogle Scholar
  61. 61.
    Jono S, Nishizawa Y, Shioi A, Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17 (6): 1135–1142.PubMedGoogle Scholar
  62. 62.
    Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278 (50): 50195–50202.PubMedGoogle Scholar
  63. 63.
    Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 2006; 70 (5): 931–937.PubMedGoogle Scholar
  64. 64.
    Moe SM. Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 2004; 24 (3): 209–216.PubMedGoogle Scholar
  65. 65.
    Maayan C, Peleg O, Eyal F, Mogle P, Rosenmann E, Bar Ziv J. Idiopathic infantile arterial calcification: a case report and review of the literature. Eur J Pediatr 1984; 142 (3): 211–215.PubMedGoogle Scholar
  66. 66.
    Qiao JH, Xie PZ, Fishbein MC, et al. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 1994; 14 (9): 1480–1497.PubMedGoogle Scholar
  67. 67.
    Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258 (5081): 468–471.PubMedGoogle Scholar
  68. 68.
    Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12 (9): 1260–1268.PubMedGoogle Scholar
  69. 69.
    Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386 (6620): 78–81.PubMedGoogle Scholar
  70. 70.
    Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol 1998; 31 (5): 987–991.PubMedGoogle Scholar
  71. 71.
    Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277 (3): 736–740.PubMedGoogle Scholar
  72. 72.
    Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93 (6): 2393–2402.PubMedGoogle Scholar
  73. 73.
    Bostrom K, Tsao D, Shen S, Wang Y, Demer LL. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 2001; 276 (17): 14044–14052.PubMedGoogle Scholar
  74. 74.
    Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002; 277 (6): 4388–4394.PubMedGoogle Scholar
  75. 75.
    Sweatt A, Sane DC, Hutson SM, Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003; 1 (1): 178–185.PubMedGoogle Scholar
  76. 76.
    Jie KS, Bots ML, Vermeer C, Witteman JC, Grobbee DE. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. Atherosclerosis 1995; 116 (1): 117–123.PubMedGoogle Scholar
  77. 77.
    Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14 (6): 1559–1567.PubMedGoogle Scholar
  78. 78.
    Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67 (6): 2295–2304.PubMedGoogle Scholar
  79. 79.
    Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21 (12): 1998–2003.PubMedGoogle Scholar
  80. 80.
    Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003; 63(3): 1003–1011.Google Scholar
  81. 81.
    Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89 (5): 747–754.PubMedGoogle Scholar
  82. 82.
    Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89 (5): 755–764.PubMedGoogle Scholar
  83. 83.
    Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23 (3): 489–494.PubMedGoogle Scholar
  84. 84.
    Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161 (6): 2035–2046.PubMedGoogle Scholar
  85. 85.
    Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84 (2): 166–178.PubMedGoogle Scholar
  86. 86.
    Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196 (8): 1047–1055.PubMedGoogle Scholar
  87. 87.
    Nitta K, Ishizuka T, Horita S, et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 2001; 89 (4): 455–458.PubMedGoogle Scholar
  88. 88.
    Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22 (4): 549–553.PubMedGoogle Scholar
  89. 89.
    Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21 (10): 1610–1616.PubMedGoogle Scholar
  90. 90.
    Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361 (9360): 827–833.PubMedGoogle Scholar
  91. 91.
    Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16 (10): 2920–2930.PubMedGoogle Scholar
  92. 92.
    Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19 (suppl. 5): V59–V66.PubMedGoogle Scholar
  93. 93.
    Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67 (6): 2383–2392.PubMedGoogle Scholar
  94. 94.
    Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20 (8): 1676–1685.PubMedGoogle Scholar
  95. 95.
    Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21 (7): 1915–1920.PubMedGoogle Scholar
  96. 96.
    Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21 (5): 1293–1299.PubMedGoogle Scholar
  97. 97.
    Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67 (3): 1070–1077.PubMedGoogle Scholar
  98. 98.
    Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88 (9): 954–960.PubMedGoogle Scholar
  99. 99.
    Banks LM, Lees B, MacSweeney JE, Stevenson JC. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest 1994; 24 (12): 813–817.PubMedGoogle Scholar
  100. 100.
    Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol 2000; 20 (2): 2346–2348.PubMedGoogle Scholar
  101. 101.
    von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106 (2): 273–278.PubMedGoogle Scholar
  102. 102.
    Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 1991; 338 (2): 355–358.PubMedGoogle Scholar
  103. 103.
    Rajendran KG, Chen SY, Sood A, Spielvogel BF, Hall IH. The anti-osteoporotic activity of amine-carboxyboranes in rodents. Biomed Pharmacother 1995; 49 (2): 131–140.PubMedGoogle Scholar
  104. 104.
    Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17 (2): 680–687.PubMedGoogle Scholar
  105. 105.
    Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273 (2): 30427–30434.PubMedGoogle Scholar
  106. 106.
    Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002; 91 (2): 570–576.PubMedGoogle Scholar
  107. 107.
    Sharma N, Desigan B, Ghosh S, Sanyal SN, Ganguly NK, Majumdar S. The role of oxidized HDL in monocyte/macrophage functions in the pathogenesis of atherosclerosis in Rhesus monkeys. Scand J Clin Lab Invest 1999; 59 (2): 215–225.PubMedGoogle Scholar
  108. 108.
    Drueke TB, Massy ZA. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 2002; 20 (2): 494–7.PubMedGoogle Scholar
  109. 109.
    Odetti P, Pronzato MA, Noberasco G, et al. Relationships between glycation and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study. Lab Invest 1994; 70 (2): 61–67.PubMedGoogle Scholar
  110. 110.
    Monnier VM, Sell DR, Nagaraj RH, et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992; 41 (suppl. 2): 36–41.PubMedGoogle Scholar
  111. 111.
    Kitauchi T, Yoshida K, Yoneda T, et al. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol 2004; 8 (2): 48–53.PubMedGoogle Scholar
  112. 112.
    Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006; 70 (2): 218–224.PubMedGoogle Scholar
  113. 113.
    Anderson HC. Molecular biology of matrix vesicles. Clin Orthop Relat Res 1995 (314): 266–280.Google Scholar
  114. 114.
    Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 1976; 35 (2): 156–162.PubMedGoogle Scholar
  115. 115.
    Tanimura A, McGregor DH, Anderson HC. Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med 1983; 172 (2): 173–177.PubMedGoogle Scholar
  116. 116.
    Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97 (2): 2307–2315.PubMedGoogle Scholar
  117. 117.
    Kim KM. Apoptosis and calcification. Scanning Microsc 1995; 9 (2): 1137–1175; discussion 1175–1178.PubMedGoogle Scholar
  118. 118.
    Kockx MM, Muhring J, Bortier H, De Meyer GR, Jacob W. Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Am J Pathol 1996; 148 (2): 1771–1777.PubMedGoogle Scholar
  119. 119.
    Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87 (2): 1055–1062.PubMedGoogle Scholar
  120. 120.
    Tjiong HL, van den Berg JW, Wattimena JL, et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16 (2): 1486–1493.PubMedGoogle Scholar
  121. 121.
    Katopodis KP, Andrikos EK, Gouva CD, et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int 2006; 26 (2): 320–327.PubMedGoogle Scholar
  122. 122.
    Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18 (2): 122–130.PubMedGoogle Scholar
  123. 123.
    Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68 (2): 1815–1824.PubMedGoogle Scholar
  124. 124.
    Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62 (2): 245–252.PubMedGoogle Scholar
  125. 125.
    Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71 (2): 438–441.PubMedGoogle Scholar
  126. 126.
    Suki WN, Zabaneh R, Cangiano J, et al. The DCOR trial--a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. J Am Soc Nephrol Abstract 2005; 16: 281A.Google Scholar
  127. 127.
    Kramsch DM, Aspen AJ, Apstein CS. Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis. J Clin Invest 1980; 65 (2): 967–981.PubMedGoogle Scholar
  128. 128.
    Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62 (2): 193–201.PubMedGoogle Scholar
  129. 129.
    Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42 (2): 96–107.PubMedGoogle Scholar
  130. 130.
    Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21 (2): 2217–2224.PubMedGoogle Scholar
  131. 131.
    Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15 (2): 770–779.PubMedGoogle Scholar
  132. 132.
    Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 318 (2): 90–98.PubMedGoogle Scholar
  133. 133.
    Martola L, Barany P, Stenvinkel P. Why do dialysis patients develop a heart of stone and bone of china? Blood Purif 2005; 23 (2): 203–210.PubMedGoogle Scholar
  134. 134.
    Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37 (2): 1410–1413.PubMedGoogle Scholar
  135. 135.
    Dao HH, Essalihi R, Graillon JF, Lariviere R, De Champlain J, Moreau P. Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. J Hypertens 2002; 20 (2): 1597–1606.PubMedGoogle Scholar
  136. 136.
    Essalihi R, Dao HH, Yamaguchi N, Moreau P. A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment. Am J Hypertens 2003; 16 (2): 103–110.PubMedGoogle Scholar
  137. 137.
    Achenbach S, Giesler T, Ropers D, et al. Detection of coronary artery stenoses by contrast-enhanced, retrospectively electrocardiographically-gated, multislice spiral computed tomography. Circulation 2001; 103 (2): 2535–2538.PubMedGoogle Scholar
  138. 138.
    Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359 (2): 1125–1126.PubMedGoogle Scholar
  139. 139.
    Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339 (2): 1972–1978.PubMedGoogle Scholar
  140. 140.
    Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22 (2): 1832–1837.PubMedGoogle Scholar
  141. 141.
    Son BK, Kozaki K, Iijima K, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006; 98 (2): 1024–1031.PubMedGoogle Scholar
  142. 142.
    McIntyre CW. Update on peritoneal dialysis solutions. Kidney Int 2007; 71 (2): 486–490.PubMedGoogle Scholar
  143. 143.
    Cozzolino M, Gallieni M, Brancaccio D. Vascular calcification in uremic conditions: new insights into pathogenesis. Semin Nephrol 2006; 26 (2): 33–37.PubMedGoogle Scholar
  144. 144.
    Drueke TB. A clinical approach to the uraemic patient with extraskeletal calcifications. Nephrol Dial Transplant 1996; 11 (suppl. 3): 37–42.PubMedGoogle Scholar
  145. 145.
    Wakabayashi Y, Kawaguchi Y, Shigematsu T, et al. Extensive peritoneal calcification as a complication of long-term CAPD. Perit Dial Int 1995; 15 (2): 369–371.PubMedGoogle Scholar
  146. 146.
    Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61 (2): 638–647.PubMedGoogle Scholar
  147. 147.
    Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007; 71 (8): 802–807.PubMedGoogle Scholar
  148. 148.
    Kalpakian MA, Mehrotra R. Vascular Calcification and Disordered Mineral Metabolism in dialysis patients. Semin Dial 2007; 20 (3): 140–144.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • M. I. Yilmaz
    • 1
  • K. Matsubara
    • 1
  • P. Stenvinkel
    • 1
  • B. Lindholm
  • Rajnish Mehrotra
    • 2
  1. 1.Divisions of Renal Medicine and Baxter Novum, Department of Clinical ScienceIntervention and Technology, Karolinska University Hospital Huddinge, Karolinska InstitutetSweden
  2. 2.David Geffen School of Medicine at UCLA, and Los Angeles Biomedical Research InstituteLos AngelesUSA

Personalised recommendations